{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:15:59Z","timestamp":1785600959945,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1245\/s10434-022-12755-y","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T17:13:19Z","timestamp":1667668399000},"page":"1312-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers"],"prefix":"10.1245","volume":"30","author":[{"given":"Nina M.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fedorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Dubard-Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Handford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Sham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-6374","authenticated-orcid":false,"given":"Meghan R.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"12755_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363. https:\/\/doi.org\/10.1200\/JCO.2011.39.8545.","journal-title":"J Clin Oncol."},{"issue":"1","key":"12755_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2014.10.008","volume":"41","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev. 2015;41(1):1\u20138. https:\/\/doi.org\/10.1016\/j.ctrv.2014.10.008.","journal-title":"Cancer Treat Rev."},{"issue":"15","key":"12755_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Katz SJ. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305.","journal-title":"J Clin Oncol"},{"issue":"6","key":"12755_CR4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2014.30","volume":"110","author":"D Leongamornlert","year":"2014","unstructured":"Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kote-Jarai Z. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110(6):1663\u201372. https:\/\/doi.org\/10.1038\/bjc.2014.30.","journal-title":"Br J Cancer"},{"issue":"4","key":"12755_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482\u201390. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5495.","journal-title":"JAMA Oncol."},{"issue":"6","key":"12755_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5009\/gnl16414","volume":"11","author":"S Welinsky","year":"2017","unstructured":"Welinsky S, Lucas AL. Familial pancreatic cancer and the future of directed screening. Gut Liver. 2017;11(6):761\u201370. https:\/\/doi.org\/10.5009\/gnl16414.","journal-title":"Gut Liver."},{"key":"12755_CR7","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.1999."},{"issue":"4","key":"12755_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/gim.2017.118","volume":"20","author":"Z Chen","year":"2018","unstructured":"Chen Z, Kolor K, Grosse SD, et al. Trends in utilization and costs of BRCA testing among women aged 18\u201364 years in the United States, 2003\u20132014. Genet Med. 2018;20(4):428\u201334. https:\/\/doi.org\/10.1038\/gim.2017.118.","journal-title":"Genet Med."},{"key":"12755_CR9","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO","volume":"35","author":"CP Childers","year":"2017","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35:3800\u20136. https:\/\/doi.org\/10.1200\/JCO.","journal-title":"J Clin Oncol."},{"issue":"1","key":"12755_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10689-016-9921-5","volume":"16","author":"DS Chun","year":"2017","unstructured":"Chun DS, Berse B, Venne VL, et al. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. Fam Cancer. 2017;16(1):41\u20139. https:\/\/doi.org\/10.1007\/s10689-016-9921-5.","journal-title":"Fam Cancer."},{"issue":"1","key":"12755_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","volume":"138","author":"T Febbraro","year":"2015","unstructured":"Febbraro T, Robison K, Wilbur JS, et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138(1):109\u201314. https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.029.","journal-title":"Gynecol Oncol."},{"issue":"7","key":"12755_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11606-009-1009-6","volume":"24","author":"DE Levy","year":"2009","unstructured":"Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med. 2009;24(7):822\u20138. https:\/\/doi.org\/10.1007\/s11606-009-1009-6.","journal-title":"J Gen Intern Med."},{"issue":"5","key":"12755_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","volume":"115","author":"LA Meyer","year":"2010","unstructured":"Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: Missed opportunities. Obstet Gynecol. 2010;115(5):945\u201352. https:\/\/doi.org\/10.1097\/AOG.0b013e3181da08d7.","journal-title":"Obstet Gynecol."},{"key":"12755_CR14","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2019."},{"issue":"1","key":"12755_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","volume":"20","author":"KG Chaffee","year":"2018","unstructured":"Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018;20(1):119\u201327. https:\/\/doi.org\/10.1038\/gim.2017.85.","journal-title":"Genet Med."},{"issue":"3","key":"12755_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148(3):556\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042.","journal-title":"Gastroenterology."},{"issue":"5","key":"12755_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/nejmoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353. https:\/\/doi.org\/10.1056\/nejmoa1603144.","journal-title":"N Engl J Med."},{"issue":"9","key":"12755_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u201375. https:\/\/doi.org\/10.1001\/jama.2010.1237.","journal-title":"JAMA."},{"issue":"15","key":"12755_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"APM Finch","year":"2014","unstructured":"Finch APM, Lubinski J, M\u00f8ller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201353. https:\/\/doi.org\/10.1200\/JCO.2013.53.2820.","journal-title":"J Clin Oncol."},{"issue":"4","key":"12755_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","volume":"13","author":"DE Levy","year":"2011","unstructured":"Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1\/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349\u201355. https:\/\/doi.org\/10.1097\/GIM.0b013e3182091ba4.","journal-title":"Genet Med."},{"issue":"05","key":"12755_CR21","first-page":"2013","volume":"14","author":"A Jolie","year":"2013","unstructured":"Jolie A. My medical choice. New York Times. 2013;14(05):2013.","journal-title":"New York Times."},{"key":"12755_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6357","author":"S Desai","year":"2016","unstructured":"Desai S, Anupam BJ. Do celebrity endorsements matter? observational study of BRCA Gene testing and mastectomy rates after Angelina Jolie\u2019s. New York Times. 2016. https:\/\/doi.org\/10.1136\/bmj.i6357.","journal-title":"New York Times."},{"issue":"1","key":"12755_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1245\/s10434-020-09123-z","volume":"28","author":"JJ Alberty-Oller","year":"2021","unstructured":"Alberty-Oller JJ, Weltz S, Santos A, et al. Adherence to NCCN guidelines for genetic testing in breast cancer patients: who are we missing? Ann Surg Oncol. 2021;28(1):281\u20136. https:\/\/doi.org\/10.1245\/s10434-020-09123-z.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"12755_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1200\/JCO.2013.51.4661","volume":"32","author":"ME Wood","year":"2014","unstructured":"Wood ME, Kadlubek P, Pham TH, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the american society of clinical oncology quality oncology practice initiative. J Clin Oncol. 2014;32(8):824\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.51.4661.","journal-title":"J Clin Oncol."},{"issue":"1","key":"12755_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/tbj.13722","volume":"26","author":"ME Wood","year":"2020","unstructured":"Wood ME, Rehman HT, Bedrosian I. Importance of family history and indications for genetic testing. Breast J. 2020;26(1):100\u20134. https:\/\/doi.org\/10.1111\/tbj.13722.","journal-title":"Breast J."},{"key":"12755_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18","volume":"37","author":"PD Beitsch","year":"2018","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37:453\u201360. https:\/\/doi.org\/10.1200\/JCO.18.","journal-title":"J Clin Oncol."},{"key":"12755_CR27","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Sebastian M, Hughes KS, et al. Consensus guideline on genetic testing for hereditary breast cancer from the American society for breast surgeons. Ann Surg Oncol. 2019;26:3025\u201331.","journal-title":"Ann Surg Oncol."},{"key":"12755_CR28","unstructured":"National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. Version 2.2017."},{"issue":"23","key":"12755_CR29","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401\u20139. https:\/\/doi.org\/10.1001\/jama.2018.6228.","journal-title":"JAMA."},{"issue":"2","key":"12755_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","volume":"110","author":"S Syngal","year":"2015","unstructured":"Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes HHS public access. Am J Gastroenterol. 2015;110(2):223\u201363. https:\/\/doi.org\/10.1038\/ajg.2014.435.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"12755_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","volume":"17","author":"CJ Paller","year":"2019","unstructured":"Paller CJ, Antonarakis ES, Beer TM, et al. Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium. Clin Genitourin Cancer. 2019;17(4):275-282.e1. https:\/\/doi.org\/10.1016\/j.clgc.2019.04.013.","journal-title":"Clin Genitourin Cancer."},{"key":"12755_CR32","unstructured":"US Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer. Accessed 20 June 2022."},{"issue":"1","key":"12755_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Cookson MS. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline part I. J Urology. 2021;205(1):14\u201321. https:\/\/doi.org\/10.1097\/JU.0000000000001375.","journal-title":"J Urology."},{"issue":"1","key":"12755_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001376","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Cookson MS. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline part II. J Urology. 2021;205(1):14\u201321. https:\/\/doi.org\/10.1097\/JU.0000000000001376.","journal-title":"J Urology"},{"issue":"3","key":"12755_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-5035-0","volume":"173","author":"MI Silver","year":"2019","unstructured":"Silver MI, Klein W, Samimi G, Minasian L, Loud J, Roberts MC. Concordance with BRCA1\/2 testing guidelines among women in The Health of Women (HOW) Study \u00ae. Breast Cancer Res Treat. 2019;173(3):719\u201326. https:\/\/doi.org\/10.1007\/s10549-018-5035-0.","journal-title":"Breast Cancer Res Treat."},{"key":"12755_CR36","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1200\/JCO.21","volume":"39","author":"FO Ademuyiwa","year":"2021","unstructured":"Ademuyiwa FO, Salyer P, Tao Y, et al. Genetic counseling and testing in African American patients with breast cancer: a nationwide survey of US breast oncologists. J Clin Oncol. 2021;39:4020\u20138. https:\/\/doi.org\/10.1200\/JCO.21.","journal-title":"J Clin Oncol."},{"issue":"6","key":"12755_CR37","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1006\/pmed.2002.1022","volume":"34","author":"K Armstrong","year":"2002","unstructured":"Armstrong K, Weber B, Ubel PA, Guerra C, Schwartz JS. Interest in BRCA1\/2 testing in a primary care population. Prev Med. 2002;34(6):590\u20135. https:\/\/doi.org\/10.1006\/pmed.2002.1022.","journal-title":"Prev Med."},{"issue":"14","key":"12755_CR38","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","volume":"293","author":"K Armstrong","year":"2005","unstructured":"Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial Differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729. https:\/\/doi.org\/10.1001\/jama.293.14.1729.","journal-title":"JAMA."},{"issue":"2","key":"12755_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/jgc4.1331","volume":"30","author":"M Triebold","year":"2021","unstructured":"Triebold M, Skov K, Erickson L, Olimb S, Puumala S, Wallace I, Stein Q. Geographical analysis of the distribution of certified genetic counselors in the United States. J Genet Couns. 2021;30(2):448\u201356. https:\/\/doi.org\/10.1002\/jgc4.1331.","journal-title":"J Genet Couns."},{"issue":"3","key":"12755_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jama.2021.24294","volume":"327","author":"JN Mafi","year":"2022","unstructured":"Mafi JN, Craff M, Vangala S, Pu T, Skinner D, Tabatabai-Yazdi C, Kahn KL. Trends in US ambulatory care patterns during the COVID-19 pandemic, 2019\u20132021. JAMA. 2022;327(3):237\u201347. https:\/\/doi.org\/10.1001\/jama.2021.24294.","journal-title":"JAMA."},{"issue":"11","key":"12755_CR41","first-page":"1251","volume":"9","author":"K Armstrong","year":"2000","unstructured":"Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisions about clinical BRCA1\/2 testing. Cancer Epidemiol Biomark Prev. 2000;9(11):1251\u20134.","journal-title":"Cancer Epidemiol Biomark Prev."},{"issue":"1\u20132","key":"12755_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0738-3991(97)00064-5","volume":"32","author":"C Hughes","year":"1997","unstructured":"Hughes C, Gomez-Caminero A, Benkendorf J, Kerner J, Isaacs C, Barter J, Lerman C. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Pat Educ Couns. 1997;32(1\u20132):51\u201362.","journal-title":"Patient Education and Counseling"},{"issue":"2","key":"12755_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000091484","volume":"9","author":"P Sankar","year":"2006","unstructured":"Sankar P, Wolpe PR, Jones NL, Cho M. How do women decide? Accepting or declining BRCA1\/2 testing in a nationwide clinical sample in the United States. Community Genet. 2006;9(2):78\u201386. https:\/\/doi.org\/10.1159\/000091484.","journal-title":"Community Genet."},{"issue":"4","key":"12755_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/1055-9965.EPI-05-0378","volume":"15","author":"ST Vadaparampil","year":"2006","unstructured":"Vadaparampil ST, Wideroff L, Breen N, Trapido E. The impact of acculturation on awareness of genetic testing for increased cancer risk among Hispanics in the year 2000 National Health Interview Survey. Cancer Epidemiol Biomark Prev. 2006;15(4):618\u201323. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0378.","journal-title":"Cancer Epidemiol Biomark Prev."},{"issue":"4","key":"12755_CR45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/cancers14041059","volume":"14","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Vlaming M, Engelhardt EG, et al. The feasibility of implementing mainstream germline genetic testing in routine cancer care\u2014a systematic review. Cancers. 2022;14(4):1059. https:\/\/doi.org\/10.3390\/cancers14041059.","journal-title":"Cancers."},{"key":"12755_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.689927","author":"MM Bellaiche","year":"2021","unstructured":"Bellaiche MM, Fan W, Walbert HJ, McClave EH, Goodnight BL, Sieling FH, Black CM. Disparity in access to oncology precision care: a geospatial analysis of driving distances to genetic counselors in the US. Front OncoL. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.689927.","journal-title":"Front OncoL."},{"issue":"1","key":"12755_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41436-019-0628-5","volume":"22","author":"M Penon-Portmann","year":"2020","unstructured":"Penon-Portmann M, Chang J, Cheng M, Shieh JT. Genetics workforce: distribution of genetics services and challenges to health care in California. Genet Med. 2020;22(1):227\u201331. https:\/\/doi.org\/10.1038\/s41436-019-0628-5.","journal-title":"Genet Med."},{"issue":"3","key":"12755_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jpm9030033","volume":"9","author":"C Villegas","year":"2019","unstructured":"Villegas C, Haga SB. Access to genetic counselors in the Southern United States. J Pers Med. 2019;9(3):33. https:\/\/doi.org\/10.3390\/jpm9030033.","journal-title":"J Pers Med."},{"issue":"1","key":"12755_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jgc4.1319","volume":"30","author":"E Boothe","year":"2021","unstructured":"Boothe E, Greenberg S, Delaney CL, Cohen SA. Genetic counseling service delivery models: a study of genetic counselors\u2019 interests, needs, and barriers to implementation. J Genet Couns. 2021;30(1):283\u201392. https:\/\/doi.org\/10.1002\/jgc4.1319.","journal-title":"J Genet Couns."},{"issue":"9","key":"12755_CR50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10552-016-0790-x","volume":"27","author":"TM Kuo","year":"2016","unstructured":"Kuo TM, Mobley LR. How generalizable are the SEER registries to the cancer populations of the USA? Cancer Causes Control. 2016;27(9):1117\u201326. https:\/\/doi.org\/10.1007\/s10552-016-0790-x.","journal-title":"Cancer Causes Control."},{"key":"12755_CR51","unstructured":"Kiesler-Starkey K, Bunch LN. Health Insurance Coverage in the United States: 2020. United States Census Bureau; 2021. Accessed September 8, 2022. https:\/\/www.census.gov\/library\/publications\/2021\/demo\/p60-274.html"},{"key":"12755_CR52","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2013."},{"key":"12755_CR53","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2013."},{"key":"12755_CR54","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 3.2013."},{"key":"12755_CR55","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 4.2013."},{"key":"12755_CR56","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2014."},{"key":"12755_CR57","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2014."},{"key":"12755_CR58","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2015."},{"key":"12755_CR59","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2015."},{"key":"12755_CR60","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2016."},{"key":"12755_CR61","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2016."},{"key":"12755_CR62","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2017."},{"key":"12755_CR63","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2017."},{"key":"12755_CR64","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2018."},{"key":"12755_CR65","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2019."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12755-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:32:31Z","timestamp":1675891951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["12755"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12755-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NMC: conceptualization, methodology, writing\u2014original draft, writing\u2014review & editing, visualization. EAR: conceptualization, methodology, writing\u2014original draft, writing\u2014review & editing. CF: conceptualization, data curation. QS: methodology, formal analysis, data curation. MD-G: conceptualization, writing \u2013 review & editing. CH: conceptualization, writing \u2013 review & editing. RY: conceptualization, writing\u2014review & editing. HHC: conceptualization, writing\u2014review & editing. JGS: conceptualization, writing\u2014review & editing. BMN: conceptualization, writing\u2014review & editing. MRF: conceptualization, methodology, formal analysis, data curation, writing\u2014original draft, writing\u2014review & editing, visualization, supervision.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}